person
as of 2026-07-01Gerhard Gründer, Prof. Dr.
at a glance
Roles: Principal Investigator, Author
KOL signal score 8
3 publications · 2 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Central Institute of Mental Health, Mannheim
Roles
Principal Investigator, Author
KOL signal
8
Publications
3 (2 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
1
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
NCT03911726—Active Not Recruiting
Publications & congress
3
Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
Schizophrenia research · 2024 · high-value
Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics.
Therapeutic drug monitoring · 2024 · high-value
PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug